XENPOZYME olipudase alfa 20mg powder for concentrate for solution for infusion (Taiwan)
Section 19A approved medicine
XENPOZYME olipudase alfa 20mg powder for concentrate for solution for infusion (Taiwan)
Section 19A approval holder
Sanofi-Aventis Australia Pty Ltd ABN 31 008 558 807
Phone
1800 818 806
Approved until
Status
Current
Medicines in short supply/unavailable
XENPOZYME olipudase alfa 20mg powder for injection vial - ARTG 394103
Indication(s)
Xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in paediatric and adult patients with type A/B (Niemann-Pick type A/B) or type B (Niemann-Pick type B).
Images
